June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Eye drop vaccination gives immunity against SARS-CoV-2
Author Affiliations & Notes
  • Norbert Franz Schrage
    Ophthalmology, ACTO e.V., Aachen, Germany
    Ophthalmology, Kliniken der Stadt Koln gGmbH, Koln, Nordrhein-Westfalen, Germany
  • Joel Blomet
    Prevor, Valmondois, Île-de-France, France
  • Frank Holzer
    Ursapharm Arzneimittel GmbH, Saarbrucken, Saarland, Germany
  • Adrien Tromme
    Faculty of Veterinary Medicine, Laboratory of Pathology, Liège, Belgium
  • Fabien Ectors
    Faculty of Veterinary Medicine, Laboratory of Pathology, Liège, Belgium
  • Daniel Desmecht
    Faculty of Veterinary Medicine, Laboratory of Pathology, Liège, Belgium
  • Footnotes
    Commercial Relationships   Norbert Schrage EYEVACC SARL, Code P (Patent); Joel Blomet EYEVACC SARL, Code P (Patent); Frank Holzer EYEVACC SARL, Code P (Patent); Adrien Tromme None; Fabien Ectors None; Daniel Desmecht EYEVACC SARL, Code P (Patent)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3796. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Norbert Franz Schrage, Joel Blomet, Frank Holzer, Adrien Tromme, Fabien Ectors, Daniel Desmecht; Eye drop vaccination gives immunity against SARS-CoV-2. Invest. Ophthalmol. Vis. Sci. 2023;64(8):3796.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Intramuscular (im) SARS-CoV-2 vaccinations reduce the individual risk with a lack of sterile immunity. New pandemic waves are the result of this problem. Mucosal vaccines make sterile immunity. Thus we try “eye drop vaccination” with approved vaccines.

Methods : 32 syrian hamsters assigned to 4 groups of each 8. All hamsters were vaccinated 2 times 2 weeks apart. Two weeks after boost vaccination, all hamsters were exposed to a disease causing intranasal SARS-CoV-2 (Wuhan type) exposure (Challenge).
Group-1: Sham PBS-buffer; Group-2 epi-ocular live SARS-CoV-2; Group-3 im vaccination Jcovden® (Johnson&Johnson vaccine); Group-4: 20 ml of Jcovden® vaccine as eye drop onto left eye. During the whole experiment, hamsters monitored: weight, health, blood samples. After challenge each 2 hamsters of Group-3 and -4 were sacrificed at day 2, day 4, and 4 at day 5. After challenge, all hamsters had daily sampling of throat fluids for qPCR on RNA coding for protein- S, -N and ORF1AB.

Results : During vaccination period, no group showed signs of local or systemic disease. The epi-ocular exposure to SARS-CoV-2 did not result in any systemic disease of the hamsters. After the second immunization hamsters showed high serum neutralizing antibodies against SARS-CoV-2 for the epi-ocular SARS-CoV2 exposed, the im and the epi-ocular J&J vaccination. No antibodies were found in the PBS group. After Challenge the PBS-“vaccinated” group showed severe weight loss and all signs of the SARS-CoV-2 disease. Hamsters being epiocular infected with SARS-CoV-2, im vaccinated and epi-ocular vaccinated hamsters stayed healthy. After epi-ocular SARS-CoV-2 and epi-ocular vaccinated hamsters showed high anti-SARS-CoV-2 IgA on their mucosa and in the blood. Anti SARS-CoV-2 IgG was high in these three groups and missing in the PBS group. The qPCR cycles increased to 28 up to 32 during the first 5 days after challenge in the immunized groups. This was not at all achieved for the sham vaccinated hamsters and first achieved for the epi-ocular SARS-CoV-2 infected hamsters followed by the epi-ocular and intramuscular vaccinated hamsters.

Conclusions : With an epi-ocular vaccination of 2x 20 ml eye-drop full immunity against SARS-CoV-2 has been achieved in all cases. Hints on sterile immunity are high mucosal IgA in epi-ocular vaccinated hamsters. Immunity and strength of immunity against Influenza and Typhus have been proven for ocular vaccination previously.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×